TITLE:
Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

CONDITION:
Gram-Positive Bacterial Infections

INTERVENTION:
Telavancin

SUMMARY:

      The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be
      safety administered to patients with bloodstream infections and whether telavancin is
      effective in treating these infections.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        - Documented S. aureus bacteremia

        Exclusion Criteria

        - Patients who had received or would have received more than 72 hours of potentially
        effective systemic antistaphylococcal therapy within 7 days prior to randomization. The
        following agents were considered potentially effective antistaphylococcal therapy:
        antistaphylococcal penicillins (including nafcillin, oxacillin, or cloxacillin),
        cephalosporins, fluoroquinolones, glycopeptides (including vancomycin and teicoplanin) and
        linezolid
      
